Verified factor-similar pair

JMOM vs MMTM

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

UMD
Similarity score
82
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • JMOM has the higher backtested relative Sharpe (1.203 vs 1.053).
  • JMOM is cheaper on dividend valuation (127 vs 174, where 100 is each fund's historical median).
  • JMOM has the stronger regression fit (adjusted R-squared 0.958 vs 0.949).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

JMOM

JPMorgan U.S. Momentum Factor ETF
UMD
Adj. R2
0.958
Rel. Sharpe
1.203
Mkt beta
1.03
AUM
US$2.1B
MER
0.12%
Valuation
127

MMTM

State Street SPDR S&P 1500 Momentum Tilt ETF
UMD
Adj. R2
0.949
Rel. Sharpe
1.053
Mkt beta
1.00
AUM
US$161M
MER
0.12%
Valuation
174

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
JMOM
+0.05
|t|
+1.1
MMTM
-0.11
|t|
-3.3
diff +0.16
HML
JMOM
-0.05
|t|
-1.4
MMTM
+0.02
|t|
+0.6
diff -0.07
RMW
JMOM
-0.06
|t|
-1.3
MMTM
+0.06
|t|
+1.6
diff -0.12
CMA
JMOM
-0.03
|t|
-0.5
MMTM
-0.02
|t|
-0.4
diff -0.01
UMD
JMOM
+0.21
|t|
+7.0
MMTM
+0.14
|t|
+6.2
diff +0.06

Why This Pair Matches

Exposure level
85
Exposure shape
74
Mkt beta diff
0.03
Rel. Sharpe diff
0.149

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

JMOM fund page MMTM fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.